Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DZNeP |
Synonyms | |
Therapy Description |
DZNeP (3-Deazaneplanocin A) inhibits S-adenosylhomocysteine hydrolase, resulting in depletion of EZH2 and inhibition of H3K27 methylation, which may promote apoptosis in cancer cells (PMID: 3790170, PMID: 19638619, PMID: 32508971). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DZNeP | 3-Deazaneplanocin A | EZH2 inhibitor 20 | DZNeP (3-Deazaneplanocin A) inhibits S-adenosylhomocysteine hydrolase, resulting in depletion of EZH2 and inhibition of H3K27 methylation, which may promote apoptosis in cancer cells (PMID: 3790170, PMID: 19638619, PMID: 32508971). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
SMARCB1 negative | atypical teratoid rhabdoid tumor | sensitive | DZNeP | Preclinical | Actionable | In a preclinical study, DZNep induced apoptosis and cell-cycle arrest and inhibited growth of SMARCB1-negative atypical teratoid rhabdoid tumor cell lines in culture (PMID: 23190500). | 23190500 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|